CytomX Therapeutics
CTMX
66 hedge funds and large institutions have $28.8M invested in CytomX Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 11 closing their positions.
3.17% less ownership
Funds ownership: 59.69% → 56.52% (-3.2%)
6% less funds holding
Funds holding: 70 → 66 (-4)
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
40% less capital invested
Capital invested by funds: $48.1M → $28.8M (-$19.3M)
70% less call options, than puts
Call options by funds: $9K | Put options by funds: $30K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$1.29M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$775K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$561K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$358K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$668K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$614K |
| 3 |
JP Morgan Chase
New York
|
-$548K |
| 4 |
ACM
Altium Capital Management
New York
|
-$482K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$461K |
CTMX Hedge Fund Activity: Q1 2025 in Review
66 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2025, worth a combined $28.8M — down 40% from $48.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CTMX and 7 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 20 added.
The largest buyer was Woodline Partners, opening a new position worth an estimated $1.29M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $668K.
- 66 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2025, down from 70 in Q4 2024.
- Funds reported $28.8M of CytomX Therapeutics stock for Q1 2025, down 40% quarter-over-quarter.
- 7 funds opened new CytomX Therapeutics positions in Q1 2025 and 11 closed out, a net change of -4 holders.
- The largest CytomX Therapeutics buyer in Q1 2025 was Woodline Partners, an estimated $1.29M added.
- The largest CytomX Therapeutics seller in Q1 2025 was Jacobs Levy Equity Management, an estimated $668K sold.
Based on aggregated 13F filings for Q1 2025.